SYK · News · 20261001N

Securities Fraud Investigation

STRYKER CORP · 2026-10-01 · Importance 36 · Surprise 50

Hagens Berman and Pomerantz are investigating whether Stryker adequately disclosed a continuing manufacturing problem in its Peripheral Vascular unit acquired through Inari Medical. The issue, initially expected to be resolved by the end of the third quarter, is now expected to persist into the fourth quarter of 2026. Reports state that the disclosure triggered an approximately 8.8% share-price decline and erased more than $10 billion in market value, while investigators assess potential violations of federal securities laws.

Key facts

• The share price decline cost Stryker over $10 billion in market value. source
• Stryker's shares dropped 8.8% after its CFO revealed that a manufacturing problem in its Peripheral Vascular unit is continuing into Q4 2026. source
• Hagens Berman has launched an investigation into Stryker following a significant drop in share price after the company's CFO disclosed that a previously reported manufacturing issue in its Peripheral Vascular unit is persisting longer than initially assured. source
• TD Cowen lowered its price target for Stryker stock from $355.00 to $298.00 while maintaining a Hold rating. source
• Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. source
• Stryker received a Buy rating from Stifel Nicolaus and a Strong Buy consensus, according to an analyst roundup. source
• Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. source